Medical Properties Trust (MPT) Financials

Medical Properties Trust (NYSE: MPT) has shown some stabilization in 2025 and early 2026, but the broader multi-year picture remains challenging. The company continues to generate positive operating cash flow in several quarters, yet earnings have been volatile, interest expense remains extremely heavy, and retained earnings are deeply negative. The balance sheet has also seen only modest improvement relative to the size of the debt load.

For retail investors, the key takeaway is that MPT still appears to be in a high-leverage turnaround phase: cash flow can be positive quarter to quarter, but the cost of debt and inconsistent profitability remain major risks.

• Q1 2026 operating cash flow turned positive at $21.3 million, showing the core business can still produce cash despite weak accounting earnings.
• Cash and equivalents improved to $425.0 million in Q1 2026, up from $396.6 million in Q3 2025.
• Total common equity increased to $4.54 billion in Q1 2026, modestly above prior quarters.
• Long-term debt edged down to $9.66 billion in Q1 2026 from $10.10 billion in Q1 2025, suggesting some balance-sheet repair.
• Q1 2026 generated $33.1 million in consolidated net income, a sharp improvement from the losses seen in much of 2025.
• Quarterly revenue has remained fairly consistent in the $105 million to $138 million range during 2025 and early 2026, indicating the top line has not collapsed.
• Dividends have continued, but the payout has been reduced substantially over time, with quarterly cash dividends per share down to $0.09 in Q1 2026 from $0.30 in Q1 2025.
• Shares outstanding have been broadly stable around 598 million to 601 million, so recent results have not been driven by major dilution in the periods shown.
• Interest expense remains the biggest issue: Q1 2026 long-term debt interest expense was $133.3 million, far exceeding quarterly revenue of $118.7 million.
• Retained earnings remain deeply negative at $(4.16) billion in Q1 2026, reflecting years of accumulated losses and dividend pressure.

Looking back over the last several years, MPT has moved from stronger profitability in 2023 to severe pressure in 2024 and 2025, followed by a partial rebound in early 2026. In 2024, net income deteriorated sharply, with several quarters showing large losses and significant non-operating charges. By 2025, quarterly earnings were still uneven, but operating cash flow improved in multiple periods, suggesting the business was able to keep generating cash even while reported net income stayed weak or negative.

The biggest structural challenge is leverage. Debt has remained near the $9.6 billion to $10.2 billion range throughout the period shown, while quarterly interest expense has often consumed most or all of revenue. That makes MPT highly sensitive to refinancing costs, asset sales, tenant health, and any decline in property income or other non-interest income.

Bottom line: MPT shows signs of stabilization, but the company is not out of the woods. Positive cash flow and higher equity are encouraging, yet the debt burden and interest expense still make this a risky name for conservative investors.